LCLu Chen

Lu Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lu Chen has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Chun Guo

    Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China

    3 shared publications
  • Dongke Yu

    Department of Pharmacy, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

    3 shared publications
  • Guimei Feng

    Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China

    3 shared publications
  • Jianyou Shi

    Department of Pharmacy, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

    3 shared publications
  • Lin Wang

    College of Food and Bioengineering, Xihun University, Chengdu, China

    3 shared publications
  • Srikanth Banda

    Department of Chemistry and Biochemistry, Florida International University, Miami, FL, United States

    3 shared publications

Latest Publications

  • Open Access

    Corrigendum: Research advances in drug therapy of endometriosis

    by Jianyou Shi, Xin Tan, Guimei Feng, Zhou Yuan, Zhongliang Jiang, Srikanth Banda, Lin Wang, Wei Zheng, Lu Chen, Dongke Yu, et al.

    Corrigendum: Research advances in drug therapy of endometriosis


  • Open Access

    Corrigendum: Research advances in drug therapy of endometriosis

    by Jianyou Shi, Xin Tan, Guimei Feng, Yuan Zhuo, Zhongliang Jiang, Srikanth Banda, Lin Wang, Wei Zheng, Lu Chen, Dongke Yu, et al.

    Corrigendum: Research advances in drug therapy of endometriosis


  • Open Access

    Research advances in drug therapy of endometriosis

    by Jianyou Shi, Xin Tan, Guimei Feng, Yuan Zhuo, Zhongliang Jiang, Srikanth Banda, Lin Wang, Wei Zheng, Lu Chen, Dongke Yu, et al.

    Endometriosis is one of the most common benign gynecological disorders in reproductive-aged women. The major symptoms are chronic pelvic pain and infertility. Despite its profound impact on women’s health and quality of life, its pathogenesis has not been fully elucidated, it cannot be cured and the long-term use of drugs yields severe side effects and hinders fertility. This review aims to present the advances in pathogenesis and the newly reported lead compounds and drugs managing endometriosis. This paper investigated Genetic changes, estrogen-dependent inflammation induction, progesterone resistance, imbalance in proliferation and apoptosis, angiogenesis, lymphangiogenesis and neurogenesis, and tissue remodeling in its pathogenesis; and explored the pharmacological mechanisms, constitutive relationships, and application prospects of each compound in the text. To date, Resveratrol, Bay1316957, and bardoxifene were effective against lesions and pain in controlled animal studies. In clinical trials, Quinagolide showed no statistical difference with the placebo group; the results of phase II clinical trial of the IL-33 antibody have not been announced yet; clinical trial stage III of vilaprisan was suspended due to drug toxicity. Elagolix was approved for the treatment of endometriosis-related pain, but clinical studies of Elagolix for the pretreatment of patients with endometriosis to before In vitro fertilization treatment have not been fulfilled. The results of a clinical study of Linzagolix in patients with moderate to severe endometriosis-related pain have not been disclosed yet. Letrozole improved the fertility of patients with mild endometriosis. For endometriosis patients with infertility, oral GnRH antagonists and aromatase inhibitors are promising drugs, especially Elagolix and Letrozole.